Bernstein launches coverage of Canada’s Tilray, Cronos and Canopy Growth but stops short of any buy ratings
November 02, 2022 at 11:15 AM EDT
Analyst Nadine Sarwat sees Cronos and Tilray as 'fairly valued' and Canopy Growth as 'meaningfully overvalued.'
